Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: BiondVax Pharmaceuticals Ltd. BVXV

MissionIRNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO to Present at BIO-Europe Spring

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that its CEO Amir Reichman will be presenting in-person at the 17th annual BIO-Europe … Continue reading

Posted in BiondVax Pharmaceuticals Ltd. BVXV | Leave a comment

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leverages Top-Tier Leadership and GMP Facility to Advance Rapid Development of New Therapeutic and Prophylactic Technologies for Multiple Diseases and Disorders

Leveraging top-tier pharmaceutical industry leadership, extensive drug development expertise, a GMP biologics manufacturing facility, and strategic collaborations with Max Planck Institute for Multidisciplinary Sciences (“MPI”) and the University Medical Center Göttingen (“UMG”), BiondVax Pharmaceuticals (NASDAQ: BVXV) is aggressively advancing development … Continue reading

Posted in BiondVax Pharmaceuticals Ltd. BVXV | Leave a comment

MissionIRNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Featured ‘Test. Optimize. Scale.’ Podcast Series

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is spotlighted in a recent episode of the “Test. Optimize. Scale.” podcast series, which features … Continue reading

Posted in BiondVax Pharmaceuticals Ltd. BVXV | Leave a comment

MissionIRNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), Collaborators Positioned to Rapidly Develop Neutralizing NanoAbs for Emerging COVID-19 Variants

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products, is working on changing the grim reality caused by the evolution of COVID-19. “The company’s leading inhaled nanosized antibody (‘NanoAb’) candidate, which is currently being … Continue reading

Posted in BiondVax Pharmaceuticals Ltd. BVXV | Leave a comment

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Nano-sized Molecules Show Powerful Impact in Preclinical Studies

With the COVID-19 disease now in its fourth year, questions abound about how the pandemic will be felt in 2023. The complex interaction of the vaccinations, available therapeutic drugs, newly emerging COVID-19 drugs, and natural immunity complicates the process of … Continue reading

Posted in BiondVax Pharmaceuticals Ltd. BVXV | Leave a comment

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) and Its Collaborators Are Positioned to Rapidly Develop COVID-19 Treatments to Neutralize Emerging Variants

The Food and Drug Administration (“FDA”) has, over the last two years, authorized several drugs as treatments for mild-to-moderate COVID-19 or as pre-exposure prophylaxis (“PrEP”) for the prevention of the disease. Most of these drugs were based on human monoclonal … Continue reading

Posted in BiondVax Pharmaceuticals Ltd. BVXV | Leave a comment

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) NanoAb Product Shows Preclinical Promise as COVID Preventative for consumers Hit by Evusheld’s EUA Withdrawal

Pioneering immunotherapy developer BiondVax Pharmaceuticals (NASDAQ: BVXV) is seeing convincingly positive outcomes for preventing and arresting disease in COVID patients during an ongoing preclinical in vivo study, even as continually evolving variants of the COVID virus are shutting down emergency … Continue reading

Posted in BiondVax Pharmaceuticals Ltd. BVXV | Leave a comment

MissionIRNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Lead NanoAb Candidate Demonstrates Significant Advantages

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, recently achieved key milestones. These include the demonstration of statistically significant positive results from a preclinical … Continue reading

Posted in BiondVax Pharmaceuticals Ltd. BVXV | Leave a comment

BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) COVID-19 NanoAb Takes Centerstage at the 2023 BIO CEO & Investor Conference

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products mainly for treating infectious and autoimmune diseases, took part in the 2023 BIO CEO & Investor Conference held at the Marriott Marquis, New York. … Continue reading

Posted in BiondVax Pharmaceuticals Ltd. BVXV | Leave a comment

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Encouraged by Nanosized Antibody Study Results as Market Forecasts Predict Rapid Growth

Immunotherapeutic product innovator BiondVax Pharmaceuticals (NASDAQ: BVXV) is focused on developing, manufacturing, and commercializing innovative nanosized antibodies (NanoAbs) for the treatment of infectious diseases and autoimmune diseases, stepping up its pursuit of disrupting the monoclonal antibody (“mAb”) market amid forecasts … Continue reading

Posted in BiondVax Pharmaceuticals Ltd. BVXV | Leave a comment